ReNeuron Group plc Director Share Purchase (2499W)
February 07 2017 - 6:32AM
UK Regulatory
TIDMRENE
RNS Number : 2499W
ReNeuron Group plc
07 February 2017
7 February 2017 AIM: RENE
ReNeuron Group plc
("ReNeuron" or the "Company")
Director Share Purchase
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, was informed on 7 February
2017 that, on the same day, Michael Hunt, the Company's Chief
Financial Officer, acquired 250,000 ordinary shares of 1p each
("Ordinary Shares") at a price of 2.64p per share.
Following this share purchase, Michael Hunt's total beneficial
interest in the Company is 2,008,471 Ordinary Shares, representing
0.063 per cent of the Company's total voting rights.
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker)
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for motor disability as a result of stroke, for
critical limb ischaemia and for the blindness-causing disease,
retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential new nanomedicine targeting cancer and as a
potential delivery system for gene therapy treatments.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
The notifications below, made in accordance with the
requirements of the EU Market Abuse Regulation, provide further
detail:
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
(Disclosure in relation to purchase of Ordinary Shares)
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ------------------------------------------------------------
a) Name Michael Hunt
--- ------------------------ ----------------------------------
2 Reason for the notification
--- ------------------------------------------------------------
a) Position/status Chief Financial Officer
--- ------------------------ ----------------------------------
b) Initial notification Initial notification
/Amendment
--- ------------------------ ----------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform,
auctioneer or auction monitor
--- ------------------------------------------------------------
a) Name ReNeuron Group plc
--- ------------------------ ----------------------------------
b) LEI N/A
--- ------------------------ ----------------------------------
4 Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii)
each date; and (iv) each place where
transactions have been conducted
--- ------------------------------------------------------------
a) Description of Ordinary Shares 0.01p
the financial
instrument, type RENE - GB00B0DZML60
of instrument
Identification
code
--- ------------------------ ----------------------------------
b) Nature of the Purchase of ordinary shares
transaction
--- ------------------------ ----------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
2.64p 250,000
--------- ----------
--- ------------------------ ----------------------------------
d) Aggregated information N/A
--- ------------------------ ----------------------------------
e) Date of the transaction 7 February 2017
--- ------------------------ ----------------------------------
f) Place of the London Stock Exchange, AIM Market
transaction
--- ------------------------ ----------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUBOURBAAURAR
(END) Dow Jones Newswires
February 07, 2017 07:32 ET (12:32 GMT)